Lidocaine Orion

Lidocaine Hydrochloride Monohydrate, the active ingredient in Lidocaine Orion, is a local anesthetic (amide type) presented as an intravenous solution for use in hospitals and clinical settings. It provides reversible loss of sensation for procedural anesthesia and can be administered intravenously to manage certain cardiac rhythm disturbances.

GNH USA supplies Lidocaine Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidocaine Orion is employed in the management of nerve conduction and cardiac electrical activity disorders.

- Local anesthesia: Provides reversible loss of sensation in targeted tissue for surgical or diagnostic procedures. - Ventricular arrhythmias: Used intravenously to suppress abnormal heart rhythms, particularly ventricular tachycardia, when other antiarrhythmics are ineffective.

Adverse reactions may occur with lidocaine administration and are categorized by frequency.

Common Side Effects: - Dizziness or light‑headedness - Tingling or numbness at the injection site - Metallic taste in the mouth - Mild hypotension - Nausea or vomiting - Transient bradycardia

Serious or Rare Side Effects: - Cardiac arrest or severe arrhythmias - Profound hypotension or cardiovascular collapse - Allergic reactions including rash, bronchospasm, or anaphylaxis - Central nervous system toxicity such as seizures - Methemoglobinemia - Respiratory depression

Lidocaine should be used with careful clinical monitoring and consideration of patient‑specific factors.

- Cardiac monitoring: Observe ECG and blood pressure during intravenous administration. - Hepatic impairment: Adjust dose or monitor plasma levels in patients with liver dysfunction. - Allergy: Avoid use in individuals with known hypersensitivity to lidocaine or amide‑type anesthetics. - Conduction disorders: Use cautiously in patients with pre‑existing heart block or severe bradycardia. - Rapid bolus injection: Do not administer large IV bolus doses; inject slowly to reduce toxicity risk. - Store at controlled room temperature: Keep below 25 °C, in original container, protected from moisture and light.

Lidocaine may interact with other medications that affect cardiac conduction or drug metabolism.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): additive effects on cardiac conduction. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase lidocaine plasma concentrations. - CYP1A2 inducers (e.g., carbamazepine, phenobarbital): reduce lidocaine effectiveness.

Moderate Interactions (Monitor Closely): - Beta‑adrenergic blockers: may enhance bradycardic response. - Diuretics (e.g., furosemide): can alter plasma protein binding and free drug levels. - General anesthetics (e.g., propofol, volatile agents): may potentiate central nervous system depression.